2019's second unicorn Gossamer raises $276M in upsized IPO offering, MPM's Harpoon makes its Nasdaq debut with $75.6M bounty
Meet 2019’s newest biotech unicorn — Gossamer Bio — which is making its debut on Nasdaq Friday with an upsized $276 million offering.
The drug developer — with a valuation of $1 billion, according to Renaissance Capital — is run by former Receptos executives, and follows the year’s first unicorn Alector $ALEC that raised $176 million at a $19 midpoint price. Investors are eagerly anticipating the performance of both, with an eye on other IPO’s waiting in line, after a turbulent December ravaged stocks across the board, including Moderna $MRNA that saw a third of its colossus $7.5 billion valuation evaporate soon after its keenly watched market debut.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.